Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response.

Autor: Zhanel GG; Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Microbiology, Health Sciences Centre, MS-673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada ggzhanel@pcs.mb.ca., Wolter KD; Established Products Clinical Development, Pfizer Inc., New York, NY, USA., Karlowsky JA; Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Microbiology, Health Sciences Centre, MS-673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada.
Jazyk: angličtina
Zdroj: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2015 Nov; Vol. 70 (11), pp. 3170-1. Date of Electronic Publication: 2015 Aug 04.
DOI: 10.1093/jac/dkv234
Databáze: MEDLINE